J.P. Morgan


J.P. Morgan Slices Price Target on Equifax Inc. (EFX) Amid Brutal Short-Term Hit from Public Data Breach

Analyst does not run from the bulls on EFX, convinced that the company can weather the storm long-term.

Clovis Oncology Inc (CLVS) PARP Product Will Not Be Hit by AstraZeneca’s FDA Approval: J.P. Morgan

The FDA approved this morning a new indication for AstraZeneca’s (NYSE:AZN) ARP inhibitor Lynparza. The new indication is for use in patients with recurrent …

Puma Biotechnology Inc (PBYI): Positive Risk/Reward Ahead of ODAC Meeting

It is a good day to be a Puma Biotechnology Inc (NASDAQ:PBYI) investors, with shares soaring 38% and FDA sentiment looking favorably on …

Acorda Therapeutics Inc (ACOR) Faces Clear Setback With Unfavorable Ampyra Ruling

On Friday, Acorda Therapeutics Inc (NASDAQ:ACOR) was met with misfortune after a district judge invalidated four patents for its multiple sclerosis drug Ampyra, …

J.P. Morgan Clips Price Target on Juno Therapeutics Inc (JUNO) Following Termination of JCAR015 Program

Juno Therapeutics Inc (NASDAQ:JUNO) shares are dropping 7% following the biotech firm’s official termination of their JCAR015 program for the treatment of patients …

Gilead Sciences, Inc. (GILD): Bictegravir HIV Data Looks Good

Gilead Sciences, Inc. (NASDAQ:GILD) announced yesterday positive phase 2 results for bictegravir vs.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts